🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

George Soros’s KLRA Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+20,000 Shares
Current Position
20,000 Shares
$440,600 Value

George Soros's KLRA Position Overview

George Soros (via Soros Fund Management LLC) currently holds 20,000 shares of Kailera Therapeutics, Inc. (KLRA) worth $440,600, representing 0.01% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, George Soros has initiated a new position in KLRA, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

George Soros's Kailera Therapeutics (KLRA) Holding Value Over Time

Track share changes against reported price movement

Quarterly Kailera Therapeutics (KLRA) Trades by George Soros

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +20,000 New Buy 20,000 $22.03

George Soros's Kailera Therapeutics Investment FAQs

George Soros first purchased Kailera Therapeutics, Inc. (KLRA) in Q2 2026, acquiring 20,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

George Soros has held Kailera Therapeutics, Inc. (KLRA) for 1 quarters since Q2 2026.

George Soros's largest addition to Kailera Therapeutics, Inc. (KLRA) was in Q2 2026, adding 20,000 shares worth $440,600.

According to the latest 13F filing for Q2 2026, George Soros's firm, Soros Fund Management LLC, owns 20,000 shares of Kailera Therapeutics, Inc. (KLRA), valued at approximately $440,600.

As of the Q2 2026 filing, Kailera Therapeutics, Inc. (KLRA) represents approximately 0.01% of George Soros's publicly disclosed stock portfolio, making it one of their key holdings.

George Soros's peak holding in Kailera Therapeutics, Inc. (KLRA) was 20,000 shares, as reported at the end of Q2 2026.